Benchmark Reiterates Buy on Biofrontera, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has reiterated a Buy rating on Biofrontera (NASDAQ:BFRI) and maintained a $7 price target.
August 16, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bruce Jackson has reiterated a Buy rating on Biofrontera and maintained a $7 price target.
The reiteration of a Buy rating and the maintenance of a $7 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100